Extended release pain relief targeting back

SpineThera is a clinical-stage pharmaceutical company focused on developing innovative injectable drugs using its proprietary micro-suspension platform technology. This technology is designed to provide a sustained-release profile for active pharmaceutical ingredients, allowing for prolonged pain relief from a single injection. The micro-suspension formulation enables the delivery of ultra-high concentrations of drugs through small needles or catheters, which is particularly beneficial for targeting challenging anatomical features. The lead investigational drug, SX600, is a novel formulation of dexamethasone aimed at treating sciatica pain, demonstrating promising results in clinical trials that suggest it could significantly improve patient outcomes while minimizing systemic exposure.

The micro-suspension technology addresses the unique safety requirements associated with epidural administration, potentially reducing the need for repeat injections and the associated risks of complications. With the current lack of FDA-approved steroids for epidural injection to treat back pain, SpineThera's SX600 represents a significant advancement in the management of radicular leg pain. The favorable safety profile and extended duration of effect observed in clinical trials position SX600 as a potential best-in-class therapy, offering a new, on-label treatment option for patients suffering from sciatica.

United States

SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our proprietary drugs offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs.

SpineThera

Company Details